Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature

[1]  N. Turner,et al.  Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment , 2021, Nature Cancer.

[2]  S. Loi,et al.  Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer , 2021 .

[3]  H. Burstein.  Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. , 2020, The New England journal of medicine.

[4]  H. Gevensleben,et al.  Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial , 2020, The Lancet. Oncology.

[5]  Y. Qiao,et al.  Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study , 2020, International journal of cancer.

[6]  Brenda F Kurland,et al.  Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. , 2020, The oncologist.

[7]  Hongyan Chen,et al.  Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer , 2019, Breast.

[8]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[9]  J. Griggs,et al.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Moore,et al.  AHNS Series – Do you know your guidelines?: Assessment and management of malnutrition in patients with head and neck cancer: Review of the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines) , 2018, Head & neck.

[11]  A. Regev,et al.  Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies , 2018, Nature Genetics.

[12]  P. V. van Diest,et al.  Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[13]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[14]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[15]  Sarika Jain,et al.  Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer , 2017, Molecular Cancer Therapeutics.

[16]  Shaohua Zhang,et al.  Receptor conversion in metastatic breast cancer: a prognosticator of survival , 2016, Oncotarget.

[17]  K. Gelmon,et al.  Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review , 2016, Cancer and Metastasis Reviews.

[18]  M. J. van de Vijver,et al.  Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[20]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.